DOCSLIB.ORG

Nonsteroidal Anti-Inflammatory Drugs (Nsaids) (Cpha Monograph)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nonsteroidal Anti-Inflammatory Drugs (Nsaids) (Cpha Monograph) Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (CPhA Monograph) https://myrxtx.ca/print/new/documents/MONOGRAPH/en/NSAIDsCPhA Health Canada Advisories New safety information for prescription-strength ibuprofen: Risk of heart attack and stroke at high doses. (2015-04) Nonsteroidal Anti-inflammatory Drugs (NSAIDs) ASA—celecoxib—diclofenac diethylamine—diclofenac potassium—diclofenac sodium—diflunisal—etodolac—floctafenine—flurbiprofen —ibuprofen—indomethacin—ketoprofen—ketorolac tromethamine—mefenamic acid—meloxicam—nabumetone—naproxen—naproxen sodium —nepafenac—piroxicam—sulindac—tenoxicam—tiaprofenic acid Anti-inflammatory—Analgesic—Antipyretic—Platelet Aggregation Inhibitor CPhA Monograph Date of Revision: October 2014 This monograph has been compiled by CPhA and reviewed by experts. It may contain information different from that found in Health Canada– Approved Product Monographs. The reader is referred to the CPS Editorial Policy for more information. For additional information regarding acetylsalicylic acid (ASA) please consult the ASA monograph. Summary Product Information Drug Route of Administration Dosage Form Strength Celecoxib Oral Capsule 100 mg, 200 mg Diclofenac diethylamine[a] Topical Gel 1.16% (11.6 mg/g), 2.32% (23.2 mg/g) Diclofenac potassium Oral Tablet 50 mg Powder for oral solution 50 mg/packet Diclofenac sodium[b] Ophthalmic Solution 0.1% Oral Enteric-coated tablet 25 mg, 50 mg Sustained-release tablet 75 mg, 100 mg Rectal Suppository 50 mg, 100 mg Topical Solution 1.5% Diflunisal Oral Tablet 250 mg, 500 mg Etodolac Oral Capsule 200 mg, 300 mg Floctafenine Oral Tablet 200 mg, 400 mg Flurbiprofen Oral Tablet 50 mg, 100 mg Ibuprofen[b] Intravenous Solution 100 mg/mL[c] Oral Capsule 200 mg,[a] 400 mg[a] Suspension 100 mg/5 mL[a] Suspension (drops) 200 mg/5 mL[a] Tablet 200 mg,[a] 300 mg,[a] 400 mg,[a] 600 mg 1 of 17 2020-03-17, 8:32 a.m. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (CPhA Monograph) https://myrxtx.ca/print/new/documents/MONOGRAPH/en/NSAIDsCPhA Drug Route of Administration Dosage Form Strength Tablet (chewable) 50 mg,[a] 100 mg[a] Indomethacin Oral Capsule 25 mg, 50 mg Rectal Suppository 50 mg, 100 mg Ketoprofen Oral Capsule 50 mg Enteric-coated tablet 50 mg, 100 mg Sustained-release tablet 200 mg Ketorolac tromethamine Ophthalmic Solution 0.4%, 0.45%, 0.5% Oral Tablet 10 mg Parenteral (im) Solution 10 mg/mL, 30 mg/mL Mefenamic acid Oral Capsule 250 mg Meloxicam Oral Tablet 7.5 mg, 15 mg Nabumetone Oral Tablet 500 mg Naproxen[b] Oral Tablet 125 mg, 250 mg, 375 mg, 500 mg Enteric-coated tablet 250 mg, 375 mg, 500 mg Sustained-release tablet 750 mg Suspension 25 mg/mL Rectal Suppository 500 mg Naproxen sodium Oral Capsule 220 mg[a] Tablet 220 mg,[a] 275 mg, 550 mg Nepafenac Ophthalmic Suspension 0.1%, 0.3% Piroxicam Oral Capsule 10 mg, 20 mg Sulindac Oral Tablet 150 mg, 200 mg Tenoxicam Oral Tablet 20 mg Tiaprofenic acid Oral Tablet 200 mg, 300 mg [a] Available without a prescription. [b] Also available in combination products. Consult Health Canada's Drug Product Database [webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp]. [c] Does not require a prescription but is generally prescribed by a medical practitioner. Indications and Clinical Use As anti-inflammatory, analgesic and antipyretic agents, NSAIDs provide symptomatic relief but do not cure the underlying disease. No NSAID has been proven superior for symptom relief. The choice of drug depends on individual risk factors such as NSAID toxicity, individual patient response, compliance potential, dosage forms, cost and available evidence. For compliance, drugs with a long half-life or available in dosage forms that allow once-daily dosing are preferred (diclofenac, ketoprofen, meloxicam, nabumetone, naproxen, tenoxicam). Health Canada-approved Indications Chronic treatment of inflammatory disorders including rheumatoid arthritis, osteoarthritis and ankylosing spondylitis. 2 of 17 2020-03-17, 8:32 a.m. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (CPhA Monograph) https://myrxtx.ca/print/new/documents/MONOGRAPH/en/NSAIDsCPhA Short-term treatment of mild to moderate pain associated with inflammation. NSAIDs are effective for musculoskeletal pain, such as muscle and joint pain, dental pain, post-operative pain, muscle strains and headache. For rapid pain relief, NSAIDs with a fast onset are preferred, while enteric-coated and sustained-release products are less suitable (see Table 7). Short-term treatment of pain due to dysmenorrhea. No NSAID has been shown to have superior efficacy in primary dysmenorrhea [Cochrane Database Syst Rev 2010;(1):CD001751]. Short-term treatment of fever. Agents with a fast onset are preferred (see Table 7). Diclofenac powder for oral solution is approved for treatment of acute migraine attacks with or without aura. Indomethacin and sulindac are approved for the treatment of acute attacks of gouty arthritis. Ketorolac is approved for short-term treatment of severe pain following major surgery. Diclofenac, ketorolac and nepafenac ophthalmic drops are approved for relief of pain and inflammation in cataract surgery. Diclofenac and ketorolac are also approved for relief of pain and inflammation in ocular trauma. Pediatrics Only ibuprofen and naproxen are approved for use in children (see Table 1). Treatment of juvenile rheumatoid arthritis. Table 1: Health Canada-approved Indications Anti-inflammatory/Analgesic Antipyretic Moderate to Mild to Severe Moderate Pain Pain Including Accompanied After Rheumatoid Ankylosing by Major Drug Arthritis Osteoarthritis Spondylitis Ophthalmic Dysmenorrhea Inflammation Surgery Fever Celecoxib Yes Yes Yes — — — Yes — Diclofenac ————— Yes—— diethylamine Diclofenac ————— Yes—— potassium Diclofenac Yes Yes — Yes — — — — sodium Diflunisal Yes Yes — — — Yes — — Etodolac Yes Yes — — — — — — Floctafenine — — — — — Yes — — Flurbiprofen Yes Yes Yes — Yes Yes — — Ibuprofen — — — — Yes Yes[a][b] Yes[c] Yes[a] Indomethacin[d] Yes Yes Yes — — Yes — — Ketoprofen Yes Yes Yes — Yes Yes — — Ketorolac ———Yes— —Yes— tromethamine Mefenamic ————YesYes—— acid Meloxicam Yes Yes — — — — — — Nabumetone Yes Yes — — — — — — Naproxen Yes[a] Yes Yes — Yes Yes — — Naproxen Yes[e] Yes[e] ——Yes[b][f] Yes[b][f] — Yes[b][f] sodium 3 of 17 2020-03-17, 8:32 a.m. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (CPhA Monograph) https://myrxtx.ca/print/new/documents/MONOGRAPH/en/NSAIDsCPhA Anti-inflammatory/Analgesic Antipyretic Moderate to Mild to Severe Moderate Pain Pain Including Accompanied After Rheumatoid Ankylosing by Major Drug Arthritis Osteoarthritis Spondylitis Ophthalmic Dysmenorrhea Inflammation Surgery Fever Nepafenac — — — Yes — — — — Piroxicam Yes Yes Yes — — — — — Sulindac[d] Yes Yes Yes — — Yes — — Tenoxicam Yes Yes Yes — — Yes — — Tiaprofenic Yes Yes — — — — — — acid [a] Approved in children for this indication. [b] Nonprescription product available for self-medication. [c] By iv infusion as adjunct to opioid analgesics. [d] Also approved for gouty arthritis. [e] Only the controlled-release product is approved for this indication. [f] Controlled-release product is not approved for this indication. Uses Without Health Canada Approval Celecoxib may be effective for reducing the number of adenomatous colonic polyps in patients with familial adenomatous polyposis (FAP) [Cochrane Database Syst Rev 2004;(2):CD004079]. Pediatrics Indomethacin is part of the treatment of Bartter syndrome [Pediatr Nephrol 2004;19(8):858-63]. Indomethacin iv has been used in premature neonates to close a patent ductus arteriosus. Indomethacin has also been used as a tocolytic to treat premature labor. There is conflicting evidence whether such use is associated with adverse fetal outcomes including constriction of the ductus arteriosus, impaired renal function and necrotizing enterocolitis [Obstet Gynecol 2005;106(1):173-9]. Ketorolac has been administered by iv injection and has been given im or iv to children 2 years of age and older. Ibuprofen may slow the loss of lung function in children with cystic fibrosis who are ≥6 years and with a forced expiratory volume over 1 minute (FEV1) >60% [Am J Respir Crit Care Med 2007;176(10):957-69], [Cochrane Database Syst Rev 2013;(6):CD001501]. Contraindications Hypersensitivity to the NSAID or to any ingredient in the formulation or component of the container. Perioperative setting of coronary artery bypass graft surgery (CABG) because of the risk of thrombotic events. The exception is low- dose ASA, which is recommended to reduce thrombotic events in the 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery [Circulation 2011;124(23):2610-42]. History of asthma or allergic-type reactions after taking NSAIDs or ASA including ASA intolerance and the Aspirin Triad (asthma, nasal polyps and ASA intolerance), since fatal anaphylactoid reactions are possible. Cross-reactivity among structurally different nonselective NSAIDs occurs. Third trimester of pregnancy because of possible premature closure of the ductus arteriosus and possible prolonged parturition. Severe uncontrolled heart failure since exacerbations can occur. Active gastric, duodenal or peptic ulcers and inflammatory bowel disease, since NSAIDs (including low-dose ASA) can increase the risk of gastrointestinal irritation, bleeding and ulceration. Cerebrovascular bleeding and other bleeding disorders because NSAIDs can increase bleeding. Severe liver impairment because most NSAIDs are metabolized in the liver. Severe renal impairment (ClCr <30 mL/minute) since NSAIDs can cause renal failure, especially in patients who have
Load more

Recommended publications
  • Colitis Caused by Non-Steroidal Anti-Inflammatory Drugs
    Postgrad Med J: first published as 10.1136/pgmj.62.730.773 on 1 August 1986. Downloaded from Postgraduate Medical Journal (1986) 62, 773-776 Colitis caused by non-steroidal anti-inflammatory drugs S. Ravi', A.C. Keat2 and E.C.B. Keat1 'Cuckfield Hospital, Cuckfield, West Sussex, and2Westminster Hospital, Horseferry Road, London SWIP2AP, UK. Summary: Four cases of acute proctocolitis associated with non-steroidal anti-inflammatory drug therapy are presented. The drugs implicated were flufenamic acid, mefenamic acid, naproxen and ibuprofen. After resolution of symptoms and signs of proctocolitis three of the four patients were subsequently rechallenged with the implicated drug: in each there was a rapid relapse. Introduction Ulcerative colitis is a disease of unknown aetiology Case reports with characteristic clinical features and a protracted course. A similar clinical picture, but running a shorter Case I and usually benign course, is occasionally seen follow- ing the administration of certain drugs. This was first A 77 year old woman was referred with intermittent noticed following the administration of antibiotics, bleeding per rectum for 6 months, associated for the often with pseudomembrane formation. Later, this last 2 months with bloody diarrhoea up to eight times was shown to be associated with infection by toxigenic daily. Previously, she had had troublesome symptoms Clostridium difficile. Until 1978, most cases were from osteoarthritis of her back and knees for which copyright. associated with treatment with clindamycin but since she had been prescribed flufenamic acid 200 mg thrice that time nearly all antibiotics have been implicated. daily. Her general health had remained good but she Other drugs capable of causing proctocolitis, though appeared pale and her haemoglobin was reduced to by different mechanisms, include phenindione (Keat & 8 g/dl.
    [Show full text]
  • What Are the Acute Treatments for Migraine and How Are They Used?
    2. Acute Treatment CQ II-2-1 What are the acute treatments for migraine and how are they used? Recommendation The mainstay of acute treatment for migraine is pharmacotherapy. The drugs used include (1) acetaminophen, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans and (5) antiemetics. Stratified treatment according to the severity of migraine is recommended: use NSAIDs such as aspirin and naproxen for mild to moderate headache, and use triptans for moderate to severe headache, or even mild to moderate headache when NSAIDs were ineffective in the past. It is necessary to give guidance and cautions to patients having acute attacks, and explain the methods of using medications (timing, dose, frequency of use) and medication use during pregnancy and breast-feeding. Grade A Background and Objective The objective of acute treatment is to resolve the migraine attack completely and rapidly and restore the patient’s normal functions. An ideal treatment should have the following characteristics: (1) resolves pain and associated symptoms rapidly; (2) is consistently effective; (3) no recurrence; (4) no need for additional use of medication; (5) no adverse effects; (6) can be administered by the patients themselves; and (7) low cost. Literature was searched to identify acute treatments that satisfy the above conditions. Comments and Evidence The acute treatment drugs for migraine generally include (1) acetaminophens, (2) non-steroidal anti-inflammatory drugs (NSAIDs), (3) ergotamines, (4) triptans, and (5) antiemetics. For severe migraines including status migrainosus and migraine attacks refractory to treatment, (6) anesthetics, and (7) corticosteroids (dexamethasone) are used (Tables 1 and 2).1)-9) There are two approaches to the selection and sequencing of these medications: “step care” and “stratified care”.
    [Show full text]
  • KETOFEN ® (Ketoprofen)
    See other side for instructions for use in cattle. KETOFEN® (ketoprofen) Injectable Solution, 100 mg/mL For intravenous use in horses. PHARMACOLOGY KETOFEN is a non-narcotic, non-steroidal anti-inflammatory agent CAUTION with analgesic and antipyretic properties. Federal law restricts this drug to use by or on the order of a In horses, intravenous dosages of ketoprofen ranging from licensed veterinarian. 0.5 to 1.5 mg/lb resulted in dosage dependent anti-inflammatory effects in the chronic adjuvant carpitis model as depicted in the DESCRIPTION following graph. Ketoprofen is a non-steroidal anti-inflammatory agent of the propionic acid class that includes ibuprofen, naproxen and fenoprofen. Active Ingredient: Each mL contains 100 mg ketoprofen/mL of aqueous solution. Inactive Ingredients: 70 mg L-Arginine/mL; citric acid (to adjust pH); benzyl alcohol, 0.025 g (as preservative). It is packaged in a multiple dose bottle. INDICATION KETOFEN® (ketoprofen) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. DOSAGE AND ADMINISTRATION The recommended dosage is 1 mg/lb (1 mL/100 lbs) of body weight administered intravenously once daily. Treatment may be repeated for up to five days. Onset of activity is within two hours with peak response by 12 hours. Use contents within 4 months of first vial puncture. CONTRAINDICATIONS Additional studies using the same model in horses have There are no known contraindications to this drug when used as shown that the effects of ketoprofen are maximal by 12 hours directed. and still measurable at 24 hours after each dosage as depicted in Intra-arterial injection should be avoided.
    [Show full text]
  • Antipyretic Efficacy of an Initial 30-Mg/Kg Loading Dose of Acetaminophen Versus a 15-Mg/Kg Maintenance Dose
    Antipyretic Efficacy of an Initial 30-mg/kg Loading Dose of Acetaminophen Versus a 15-mg/kg Maintenance Dose Jean Marc Tre´luyer, MD, PhD*; Sylvie Tonnelier, PharmD*; Philippe d’Athis‡; Beatrice Leclerc§; Isabelle Jolivet-Landreau, MD§; and Ge´rard Pons, MD, PhD* ABSTRACT. Objective. To compare the antipyretic comfort.1 Among the available antipyretic agents, efficacy of an initial 30-mg/kg acetaminophen loading acetaminophen is one of the most widely used be- dose versus a 15-mg/kg maintenance dose. cause it has an antipyretic efficacy equivalent to the Methods. A double-blind, parallel-group, random- other antipyretic drugs and a good safety profile.2–4 ized clinical trial was conducted. A total of 121 febrile Acetaminophen antipyretic efficacy is dose-depen- (rectal temperature between 39°C and 40°C) but other- dent.5,6 The recommended dose is 15 mg/kg every 6 wise healthy outpatients who were 4 months to 9 years of 2 age and weighed 4 to 26 kg were assigned randomly to 1 hours. Following this dosing schedule, it usually -takes several hours after the first acetaminophen ad ؍ and 30 mg/kg (n (62 ؍ of the dose groups: 15 mg/kg (n 59). ministration to obtain the maximal clinical efficacy of Results. In an “intention to treat” analysis, the time to the drug.7 Therefore, Mahar et al8 suggested a phys- obtain a temperature lower than 38.5°C was significantly ical “cold therapy” at the initiation of the chemical shorter in the 30-mg/kg than in the 15-mg/kg group treatment to decrease the time course to antipyretic minutes vs 139 ؎ 113 minutes).
    [Show full text]
  • Native State Stabilization by Nsaids Inhibits Transthyretin Amyloidogenesis from the Most Common Familial Disease Variants
    Laboratory Investigation (2004) 84, 545–552 & 2004 USCAP, Inc All rights reserved 0023-6837/04 $25.00 www.laboratoryinvestigation.org Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants Sean R Miller, Yoshiki Sekijima and Jeffery W Kelly Department of Chemistry and The Skaggs Institute of Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA Transthyretin (TTR) tetramer dissociation and misfolding affords a monomeric amyloidogenic intermediate that misassembles into aggregates including amyloid fibrils. Amyloidogenesis of wild-type (WT) TTR causes senile systemic amyloidosis (SSA), whereas fibril formation from one of the more than 80 TTR variants leads to familial amyloidosis, typically with earlier onset than SSA. Several nonsteroidal anti-inflammatory drugs (NSAIDs) stabilize the native tetramer, strongly inhibiting TTR amyloid fibril formation in vitro. Structure-based designed NSAID analogs are even more potent amyloid inhibitors. The effectiveness of several NSAIDs, including diclofenac, diflunisal, and flufenamic acid, as well as the diclofenac analog, 2–[(3,5-dichlorophenyl) amino] benzoic acid (inhibitor 1), has been demonstrated against WT TTR amyloidogenesis. Herein, the efficacy of these compounds at preventing acid-induced fibril formation and urea-induced tetramer dissociation of the most common disease-associated TTR variants (V30M, V122I, T60A, L58H, and I84S) was evaluated. Homotetramers of these variants were employed for the studies within, realizing that the tetramers in compound heterozygote patients are normally composed of a mixture of WT and variant subunits. The most common familial TTR variants were stabilized substantially by flufenamic acid and inhibitor 1, and to a lesser extent by diflunisal, against acid-mediated fibril formation and chaotrope denaturation, suggesting that this chemotherapeutic option is viable for patients with familial transthyretin amyloidosis.
    [Show full text]
  • Efficacy and Safety of Celecoxib
    ORIGINAL PAPER Nagoya J. Med. Sci. 77. 81 ~ 93, 2015 EFFICACY AND SAFETY OF CELECOXIB COMPARED WITH PLACEBO AND ETODOLAC FOR ACUTE POSTOPERATIVE PAIN: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL-GROUP, CONTROLLED TRIAL NAOKI ISHIGURO1, MD, PhD; AKIO HANAOKA2, MS; TOSHIYUKI OKADA2, MS; and MASANORI ITO3, PhD 1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan 2Clinical Development 1, Astellas Pharma Inc., Tokyo, Japan 3Global Data Science, Astellas Pharma Global Development Inc., Northbrook, IL, US ABSTRACT Celecoxib is a nonsteroidal anti-inflammatory drug (selective cyclooxygenase-2 inhibitor) that is widely used. The efficacy and safety of celecoxib for treatment of acute postoperative pain were evaluated in Japanese patients. The objective was to assess whether celecoxib showed superiority over placebo treatment and non-inferiority versus etodolac (another selective cyclooxygenase-2 inhibitor) that has been widely used for the management of acute pain. A multicenter, double-blind, randomized, parallel-group, controlled study was performed, in which 616 patients with postoperative pain received celecoxib, etodolac, or placebo. Their impressions of study drug efficacy (overall assessment) and pain intensity were evaluated. Based on each patient’s overall assessment of pain, the efficacy rate was 63.7% in the placebo group, 76.2% in the celecoxib group, and 68.0% in the etodolac group, with these results demonstrating superiority of celecoxib to placebo and noninferiority versus etodolac. The efficacy rate was significantly higher in the celecoxib group than in the etodolac group. There were no adverse events specific to celecoxib, and the safety of celecoxib was similar to that of placebo. Celecoxib was superior to etodolac for controlling acute postoperative pain.
    [Show full text]
  • New Restrictions on Celecoxib (Celebrex) Use and the Withdrawal of Valdecoxib (Bextra)
    Early release, published at www.cmaj.ca on April 15, 2005. Subject to revision. HEALTH AND DRUG ALERTS P RACTICE New restrictions on celecoxib (Celebrex) use and the withdrawal of valdecoxib (Bextra) Early release, published at www.cmaj.ca on Apr. 15, 2005. Subject to revision. Reason for posting: Coxibs, v. 0.5%; risk ratio 3.7, 95% CI the class of NSAIDs that selec- 1.0–13.5).2 Amid concerns about Table 1: The degree of inhibition of COX-2 relative tively inhibit cyclooxygenase 2 reports of severe cutaneous reac- to COX-1 for various NSAIDs (COX-2), were designed to re- tions (Stevens–Johnson syn- NSAID type COX-2 selectivity* duce joint pain and inflamma- drome, erythema multiforme, tion without causing the gastric toxic epidermal necrolysis) COX-2 selective inhibitors epithelial adverse effects typical among patients taking valde- Rofecoxib 80 of nonselective NSAIDs. Rofe- coxib,5 the drug was removed Etodolac 23 coxib (Vioxx) was withdrawn from the market. Meloxicam 11 from the market in September Celecoxib 9 2004 over concerns about car- What to do: COX-2 inhibitors Nonselective NSAIDs diovascular adverse effects, and appear to increase the risk of car- Diclofenac 4 key safety trials involving cele- diovascular adverse events in a Sulindac 3 coxib (Celebrex)1 and valdecoxib dose-related fashion, and all pa- Piroxicam 2 (Bextra)2 have recently been tients should be informed of this. Ibuprofen 0.4 published. Health Canada now Calculating the patient’s baseline Naproxen 0.3 recommends new restrictions on risk of cardiovascular disease Indomethacin 0.2 celecoxib use, and valdecoxib (e.g., with Framingham risk cal- Ketorolac 0.003 has been taken off the market.3 culators) may be wise, and cele- Note: COX = cyclooxygenase.
    [Show full text]
  • Clinical Report—Fever and Antipyretic Use in Children Abstract
    Guidance for the Clinician in Rendering Pediatric Care Clinical Report—Fever and Antipyretic Use in Children Janice E. Sullivan, MD, Henry C. Farrar, MD, and the abstract SECTION ON CLINICAL PHARMACOLOGY AND THERAPEUTICS, and COMMITTEE ON DRUGS Fever in a child is one of the most common clinical symptoms managed by pediatricians and other health care providers and a frequent cause KEY WORDS fever, antipyretics, children of parental concern. Many parents administer antipyretics even when ABBREVIATIONS there is minimal or no fever, because they are concerned that the child NSAID—nonsteroidal anti-inflammatory drug must maintain a “normal” temperature. Fever, however, is not the The guidance in this report does not indicate an exclusive primary illness but is a physiologic mechanism that has beneficial course of treatment or serve as a standard of medical care. effects in fighting infection. There is no evidence that fever itself wors- Variations, taking into account individual circumstances, may be ens the course of an illness or that it causes long-term neurologic appropriate. complications. Thus, the primary goal of treating the febrile child This document is copyrighted and is property of the American Academy of Pediatrics and its Board of Directors. All authors should be to improve the child’s overall comfort rather than focus on have filed conflict of interest statements with the American the normalization of body temperature. When counseling the parents Academy of Pediatrics. Any conflicts have been resolved through or caregivers of a febrile child, the general well-being of the child, the a process approved by the Board of Directors.
    [Show full text]
  • Nsaids: Dare to Compare 1997
    NSAIDs TheRxFiles DARE TO COMPARE Produced by the Community Drug Utilization Program, a Saskatoon District Health/St. Paul's Hospital program July 1997 funded by Saskatchewan Health. For more information check v our website www.sdh.sk.ca/RxFiles or, contact Loren Regier C/O Pharmacy Department, Saskatoon City Hospital, 701 Queen St. Saskatoon, SK S7K 0M7, Ph (306)655-8506, Fax (306)655-8804; Email [email protected] We have come a long way from the days of willow Highlights bark. Today salicylates and non-steroidal anti- • All NSAIDs have similar efficacy and side inflammatory drugs (NSAIDs) comprise one of the effect profiles largest and most commonly prescribed groups of • In low risk patients, Ibuprofen and naproxen drugs worldwide.1 In Saskatchewan, over 20 may be first choice agents because they are different agents are available, accounting for more effective, well tolerated and inexpensive than 300,000 prescriptions and over $7 million in • Acetaminophen is the recommended first line sales each year (Saskatchewan Health-Drug Plan agent for osteoarthritis data 1996). Despite the wide selection, NSAIDs • are more alike than different. Although they do Misoprostol is the only approved agent for differ in chemical structure, pharmacokinetics, and prophylaxis of NSAID-induced ulcers and is to some degree pharmacodynamics, they share recommended in high risk patients if NSAIDS similar mechanisms of action, efficacy, and adverse cannot be avoided. effects. week or more to become established. For this EFFICACY reason, an adequate trial of 1-2 weeks should be NSAIDs work by inhibiting cyclooxygenase (COX) allowed before increasing the dose or changing to and subsequent prostaglandin synthesis as well as another NSAID.
    [Show full text]
  • Food and Drug Administration, HHS § 201.323
    Food and Drug Administration, HHS § 201.323 liver damage or gastrointestinal bleed- calcium, choline salicylate, magnesium ing). OTC drug products containing in- salicylate, or sodium salicylate] or ternal analgesic/antipyretic active in- other pain relievers/fever reducers. [Ac- gredients may cause similar adverse ef- etaminophen and (insert one nonste- fects. FDA concludes that the labeling roidal anti-inflammatory analgesic/ of OTC drug products containing inter- antipyretic ingredient—including, but nal analgesic/antipyretic active ingre- not limited to aspirin, carbaspirin cal- dients should advise consumers with a cium, choline salicylate, magnesium history of heavy alcohol use to consult salicylate, or sodium salicylate] may a physician. Accordingly, any OTC cause liver damage and stomach bleed- drug product, labeled for adult use, ing.’’ containing any internal analgesic/anti- (b) Requirements to supplement ap- pyretic active ingredients (including, proved application. Holders of approved but not limited to, acetaminophen, as- applications for OTC drug products pirin, carbaspirin calcium, choline sa- that contain internal analgesic/anti- licylate, ibuprofen, ketoprofen, magne- pyretic active ingredients that are sub- sium salicylate, naproxen sodium, and ject to the requirements of paragraph sodium salicylate) alone or in combina- (a) of this section must submit supple- tion shall bear an alcohol warning ments under § 314.70(c) of this chapter statement in its labeling as follows: to include the required warning in the (1) Acetaminophen. ‘‘Alcohol Warn- product’s labeling. Such labeling may ing’’ [heading in boldface type]: ‘‘If you be put into use without advance ap- consume 3 or more alcoholic drinks proval of FDA provided it includes the every day, ask your doctor whether exact information included in para- you should take acetaminophen or graph (a) of this section.
    [Show full text]
  • CELEBREX™ (Celecoxib Capsules)
    01/05/99 4:16 PM draft label 1 CELEBREX™ 2 (celecoxib capsules) 3 4 5 DESCRIPTION 6 7 CELEBREX (celecoxib) is chemically designated as 4-[5-(4-methylphenyl)-3- 8 (trifluoromethyl)-1H-pyrazol-1-yl] benzenesulfonamide and is a diaryl substituted 9 pyrazole. It has the following chemical structure: 10 O NH2 S O N N CF3 11 CH3 12 13 14 The empirical formula for celecoxib is C17H14F3N3O2S, and the molecular weight is 381.38. 15 16 CELEBREX oral capsules contain 100 mg and 200 mg of celecoxib. 17 18 The inactive ingredients in CELEBREX capsules include: croscarmellose sodium, edible 19 inks, gelatin, lactose monohydrate, magnesium stearate, povidone, sodium lauryl sulfate 20 and titanium dioxide. 21 22 CLINICAL PHARMACOLOGY 23 24 Mechanism of Action 25 CELEBREX is a nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, 26 analgesic, and antipyretic activities in animal models. The mechanism of action of 27 CELEBREX is believed to be due to inhibition of prostaglandin synthesis, primarily via 28 inhibition of cyclooxygenase-2 (COX-2), and at therapeutic concentrations in humans, 29 CELEBREX does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme. 30 31 Pharmacokinetics 32 33 Absorption 34 Peak plasma levels of celecoxib occur approximately 3 hrs after an oral dose. Both peak 35 plasma levels (Cmax) and area under the curve (AUC) are roughly dose proportional 36 across the clinical dose range of 100-200 mg studied. At higher doses, under fasting 37 conditions, there is a less than proportional increase in Cmax and AUC which is thought 38 to be due to the low solubility of the drug in aqueous media.
    [Show full text]
  • IBUPROFEN Ibuprofen Film-Coated Tablet 200 Mg
    NEW ZEALAND CONSUMER MEDICINE INFORMATION IBUPROFEN Ibuprofen film-coated tablet 200 mg IBUPROFEN also relieves fever • asthma, wheezing or What is in this leaflet (high temperature). shortness of breath • swelling of the face, lips, Please read this leaflet carefully Although IBUPROFEN can relieve tongue which may cause before you start IBUPROFEN. the symptoms of pain and difficulty in swallowing or inflammation, it will not cure your breathing This leaflet answers some common condition. • hives, itching or skin rash. questions about IBUPROFEN. • stomach ache, fever, chills, IBUPROFEN contains the active nausea and vomiting It does not contain all the available ingredient ibuprofen. Ibuprofen • fainting information. It does not take the belongs to a group of medicines place of talking to your doctor or called non-steroidal anti- If you are allergic to aspirin or pharmacist. inflammatory drugs (or NSAIDs). NSAID medicines and take IBUPROFEN, these symptoms All medicines have risks and Your doctor may have prescribed may be severe. benefits. Your doctor has weighed this medicine for another reason. the risks of you taking IBUPROFEN Do not take IBUPROFEN if you against the benefits they expect it Ask your doctor if you have any are in your third trimester of will have for you. questions about why this pregnancy. medicine has been prescribed for It may affect your developing baby if If you have any concerns about you. you take it during this time. taking this medicine, ask your doctor or pharmacist. Many medicines used to treat Do not take IBUPROFEN if you headache, period pain and other have (or have previously) Keep this leaflet with the aches and pains contain aspirin or vomited blood or material that medicine.
    [Show full text]